Table 1. Glucokinase activators in clinical development. Despite the discontinuation of some programs from large pharmas, including Merck & Co. Inc. (NYSE:MRK), Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), AstraZeneca plc (LSE:AZN; NYSE:AZN) and Roche (SIX:ROG; OTCQX:RHHBY), at least eight glucokinase activators remain in clinical development.
Source: BCIQ: BioCentury Online Intelligence

Company

Product

Development

Advinus Therapeutics Ltd.

GKM-001

Phase I/II

Array BioPharma Inc. (NASDAQ:ARRY)

ARRY-403 (formerly AMG151)A

Phase II

Daiichi Sankyo Co. Ltd. (Tokyo:4568)

DS-7309

Phase I

Pfizer Inc. (NYSE:PFE)

PF-04937319

Phase II

Roche

HMS5552 (formerly RO5305552)

Phase I

Teijin Pharma Ltd.

TMG-123

Phase I

TransTech Pharma Inc.

GKI-399 (TTP399)

Phase I/II

Zydus Cadila Group (NSE:CADILAHC; BSE:532321)

ZYGK1

Phase I

AThis year, Amgen Inc. (NASDAQ:AMGN) returned all rights to AMG151 to Array BioPharma.